reports
Pantoro Limited: 1 director
A director at Pantoro Limited sold 1,000,000 shares at 0.086AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Gear Energy Ltd: 1 director
A director at Gear Energy Ltd bought 705,500 shares at 0.730CAD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Landstar to Participate in Bank of America 2024 Annual Investment Conf...
Landstar to Participate in Bank of America 2024 Annual Investment Conference JACKSONVILLE, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ:LSTR) announced today its participation in the Bank of America 2024 Annual Investment Conference. Landstar’s “fireside chat” discussion begins at 10:20 a.m. ET on Tuesday, May 14. It will be broadcast live via the Internet at ; click on "Webcasts." The Bank of America 2024 Annual Investment Conference webcast will be available on Landstar’s website through May 22. For more information about the webcast, please contact Landstar’s In...
Form 8.3 - Balanced Commercial Property Trust Limited
Form 8.3 - Balanced Commercial Property Trust Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant se...
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 500,000 shares at 1.000SGD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Hunan Coran New Energy Co Ltd: 3 directors
Three Directors at Hunan Coran New Energy Co Ltd bought 63,600 shares at between 4.246CNY and 4.280CNY. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Form 8.3 - Alpha Financial Markets Consulting Plc
Form 8.3 - Alpha Financial Markets Consulting Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securi...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psy...
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusiv...
Form 8.3 - Abrdn European Logistics Income Plc
Form 8.3 - Abrdn European Logistics Income Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securitie...
Tompkins Financial Corp: 1 director
A director at Tompkins Financial Corp sold 4,099 shares at 0.000USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or sec...
Caledonia Mining Corporation Plc: Results of Annual General Meeting
Caledonia Mining Corporation Plc: Results of Annual General Meeting ST HELIER, Jersey, May 07, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("the Company") (NYSE American, AIM and VFEX: CMCL) announces the results of its annual general meeting of shareholders (the “AGM”) held at St Helier, Jersey today. The total number of shareholders present in person or by proxy at the AGM was 96, representing 62.28% of the Company’s outstanding voting shares. The table below shows the proxy votes received on resolutions 1(a) to 1(h), which were duly passed by a show of hands, to rea...
Crown Castle’s Highly Qualified Board of Directors is Driving Strategi...
Crown Castle’s Highly Qualified Board of Directors is Driving Strategic Actions to Enhance Value Refreshed Board Has Deep Expertise in Telecom, Towers and Fiber Industries as well as C-Suite and Investment Professional Experience Boots Capital Nominees Lack Additive Skills Crown Castle Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Director Nominees on the WHITE Proxy Card or Voting Instruction Form HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today sent a letter to shareholders in connection with its upcoming 2024 ...
Chin Hin Group Berhad: 1 director
A director at Chin Hin Group Berhad bought 1,000,000 shares at 2.700MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Cognition Therapeutics Reports Financial Results for the First Quarter...
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “During the ...
Neuronetics Reports Record First Quarter 2024 Financial and Operating ...
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first qua...
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The sessions will be webcast and can be accessed b...
Amesite Announces Strategic Five-Year Partnership with Franciscan Miss...
Amesite Announces Strategic Five-Year Partnership with Franciscan Missionaries of Our Lady University to Deliver Healthcare Training for Healthcare Professionals Franciscan Missionaries of Our Lady University is Sixth Contract Win Since Introducing No Setup-fee Plan DETROIT, May 07, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces a five-year (5) partnership with Franciscan Missionaries of Our Lady University to deliver healthcare training progra...
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis...
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumabData to be presented in a KOL event to be held Tuesday, May 7, 2024 at 8:00 am ET, register SAN MATEO, Calif. and SINGAPORE, May 07,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.